share_log

JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125

JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125

JMP证券维持蓝图药物的市场跑赢大盘,将目标股价上调至125美元
Benzinga ·  05/03 15:02

JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the price target from $114 to $125.

JMP证券分析师雷尼·本杰明维持Blueprint Medicines(纳斯达克股票代码:BPMC)的市场跑赢大盘,并将目标股价从114美元上调至125美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发